Afficher la notice abrégée

Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorKOROBELNIK, Jean-Francois
dc.contributor.authorLOEWENSTEIN, Anat
dc.contributor.authorELDEM, Bora
dc.contributor.authorJOUSSEN, Antonia M.
dc.contributor.authorKOH, Adrian
dc.contributor.authorLAMBROU, George N.
dc.contributor.authorLANZETTA, Paolo
dc.contributor.authorLI, Xiaoxin
dc.contributor.authorLÖVESTAM-ADRIAN, Monica
dc.contributor.authorNAVARRO, Rafael
dc.contributor.authorOKADA, Annabelle A.
dc.contributor.authorPEARCE, Ian
dc.contributor.authorRODRÍGUEZ, Francisco J.
dc.contributor.authorWONG, David T.
dc.contributor.authorWU, Lihteh
dc.date.accessioned2021-03-30T10:08:49Z
dc.date.available2021-03-30T10:08:49Z
dc.date.issued2021-02-02
dc.identifier.issn0721-832Xen_US
dc.identifier.urioai:crossref.org:10.1007/s00417-021-05097-0
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26825
dc.description.abstractEnAbstract Purpose Following the first wave of the COVID-19 pandemic in early 2020, the easing of strict measures to reduce its spread has led to a resurgence of cases in many countries at both the national and local level. This article addresses how guidance for ophthalmologists on managing patients with retinal disease receiving intravitreal injections of anti-vascular endothelial growth factor (VEGF) during the pandemic should be adapted to the local epidemic pressure, with more or less stringent measures implemented according to the ebb and flow of the pandemic. Methods The Vision Academy’s membership of international retinal disease experts analyzed guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic and graded the recommendations according to three levels of increasing epidemic pressure. The revised recommendations were discussed, refined, and voted on by the 14-member Vision Academy Steering Committee for consensus. Results Protocols to minimize the exposure of patients and healthcare staff to COVID-19, including use of personal protective equipment, physical distancing, and hygiene measures, should be routinely implemented and intensified according to local infection rates and pressure on the hospital/clinic or healthcare system. In areas with many COVID-19-positive clusters, additional measures including pre-screening of patients, postponement of non-urgent appointments, and simplification of complex intravitreal anti-VEGF regimens should be considered. Treatment prioritization for those at greatest risk of irreversible vision loss should be implemented in areas where COVID-19 cases are increasing exponentially and healthcare resources are strained. Conclusion Consistency in monitoring of local infection rates and adjustment of clinical practice accordingly will be required as we move forward through the COVID-19 era. Ophthalmologists must continue to carefully weigh the risk–benefits to minimize the exposure of patients and healthcare staff to COVID-19, ensure that patients receive sight-saving treatment, and avoid the potential long-term impact of prolonged treatment postponement.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.sourcecrossref
dc.subjectRetinal disease
dc.subjectOphthalmology
dc.subjectCOVID-19
dc.subjectCoronavirus
dc.subjectRecommendations
dc.subjectVision Academy
dc.title.enAnti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s00417-021-05097-0en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33528647en_US
bordeaux.journalGraefe's Archive for Clinical and Experimental Ophthalmologyen_US
bordeaux.page567–574en_US
bordeaux.volume259en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamLEHA_BPH
bordeaux.teamLEHA_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcedissemin
hal.identifierhal-03185355
hal.version1
hal.date.transferred2021-03-30T10:08:54Z
hal.exporttrue
workflow.import.sourcedissemin
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Graefe's%20Archive%20for%20Clinical%20and%20Experimental%20Ophthalmology&rft.date=2021-02-02&rft.volume=259&rft.spage=567%E2%80%93574&rft.epage=567%E2%80%93574&rft.eissn=0721-832X&rft.issn=0721-832X&rft.au=KOROBELNIK,%20Jean-Francois&LOEWENSTEIN,%20Anat&ELDEM,%20Bora&JOUSSEN,%20Antonia%20M.&KOH,%20Adrian&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir
Thumbnail
Nom:
BPH_GACEO_2021_Korobelnik_2.pdf
Taille:
314.5Ko
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée